FDA Classifies Post-Birth Chromosome Checker as Safe Class II Device
Published Date: 8/21/2025
Rule
Summary
The FDA is officially putting the postnatal chromosomal copy number variation detection system into a special safety category called Class II. This means the device will have clear rules to keep it safe and effective, helping patients get access to new, helpful technology faster. This change affects device makers and aims to cut red tape without compromising safety, with no extra costs announced.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Postnatal CNV Test Reclassified to Class II
The FDA is classifying the postnatal chromosomal copy number variation (CNV) detection system as Class II (special controls). The agency says the special controls will be identified in this order and codified, and that the Class II classification provides a reasonable assurance of safety and effectiveness while reducing regulatory burdens.
Faster Patient Access to CNV Tests
You may get better access to postnatal chromosomal copy number variation detection systems because the FDA says Class II classification will enhance patients' access to beneficial innovative devices by reducing regulatory burdens. The FDA also states the classification provides a reasonable assurance of safety and effectiveness.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in